83 related articles for article (PubMed ID: 2208125)
1. Mechanisms of resistance of confluent human and rat colon cancer cells to anthracyclines: alteration of drug passive diffusion.
Pelletier H; Millot JM; Chauffert B; Manfait M; Genne P; Martin F
Cancer Res; 1990 Oct; 50(20):6626-31. PubMed ID: 2208125
[TBL] [Abstract][Full Text] [Related]
2. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution.
Baldini N; Scotlandi K; Serra M; Shikita T; Zini N; Ognibene A; Santi S; Ferracini R; Maraldi NM
Eur J Cell Biol; 1995 Nov; 68(3):226-39. PubMed ID: 8603675
[TBL] [Abstract][Full Text] [Related]
3. Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vivo.
Genne P; Dimanche-Boitrel MT; Mauvernay RY; Gutierrez G; Duchamp O; Petit JM; Martin F; Chauffert B
Cancer Res; 1992 May; 52(10):2797-801. PubMed ID: 1581892
[TBL] [Abstract][Full Text] [Related]
4. Amiodarone-induced enhancement of doxorubicin and 4'-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo.
Chauffert B; Martin M; Hammann A; Michel MF; Martin F
Cancer Res; 1986 Feb; 46(2):825-30. PubMed ID: 3940645
[TBL] [Abstract][Full Text] [Related]
5. Confluence-dependent resistance to doxorubicin in human MDA-MB-231 breast carcinoma cells requires hypoxia-inducible factor-1 activity.
Fang Y; Sullivan R; Graham CH
Exp Cell Res; 2007 Mar; 313(5):867-77. PubMed ID: 17289019
[TBL] [Abstract][Full Text] [Related]
6. The nuclear membrane in multidrug resistance: microinjection of epirubicin into bladder cancer cell lines.
Featherstone JM; Speers AG; Lwaleed BA; Hayes MC; Cooper AJ; Birch BR
BJU Int; 2005 May; 95(7):1091-8. PubMed ID: 15839939
[TBL] [Abstract][Full Text] [Related]
7. Serum concentrations of amiodarone required for an in vivo modulation of anthracycline resistance.
Genne P; Coudert B; Pelletier H; Girardot C; Martin F; Chauffert B
Anticancer Res; 1989; 9(6):1655-9. PubMed ID: 2627117
[TBL] [Abstract][Full Text] [Related]
8. Stable differentiation of a human colon adenocarcinoma cell line by sodium butyrate is associated with multidrug resistance.
Ho SB; Yan PS; Dahiya R; Neuschwander-Tetri BA; Basbaum C; Kim YS
J Cell Physiol; 1994 Aug; 160(2):213-26. PubMed ID: 7913708
[TBL] [Abstract][Full Text] [Related]
9. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.
Mankhetkorn S; Dubru F; Hesschenbrouck J; Fiallo M; Garnier-Suillerot A
Mol Pharmacol; 1996 Mar; 49(3):532-9. PubMed ID: 8643093
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.
Slovak ML; Hoeltge GA; Dalton WS; Trent JM
Cancer Res; 1988 May; 48(10):2793-7. PubMed ID: 2896069
[TBL] [Abstract][Full Text] [Related]
11. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
12. Anthracyclines.
Sinha BK; Politi PM
Cancer Chemother Biol Response Modif; 1990; 11():45-57. PubMed ID: 2223402
[TBL] [Abstract][Full Text] [Related]
13. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity.
Faderl S; Estrov Z; Kantarjian HM; Harris D; Van Q; Fokt I; Przewloka T; Godlewski C; Woynarowski JM; Priebe W
Anticancer Res; 2001; 21(6A):3777-84. PubMed ID: 11911247
[TBL] [Abstract][Full Text] [Related]
14. Effect of structural modifications of anthracyclines on the ability to overcome drug resistance of cancer cells.
Wasowska M; Wietrzyk J; Opolski A; Oszczapowicz J; Oszczapowicz I
Anticancer Res; 2006; 26(3A):2009-12. PubMed ID: 16827137
[TBL] [Abstract][Full Text] [Related]
15. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines.
Dong J; Naito M; Tatsuta T; Seimiya H; Johdo O; Tsuruo T
Oncol Res; 1995; 7(5):245-52. PubMed ID: 8534930
[TBL] [Abstract][Full Text] [Related]
16. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms.
Wu W; Luo Y; Sun C; Liu Y; Kuo P; Varga J; Xiang R; Reisfeld R; Janda KD; Edgington TS; Liu C
Cancer Res; 2006 Jan; 66(2):970-80. PubMed ID: 16424032
[TBL] [Abstract][Full Text] [Related]
17. Role of glutathione S-transferases in the resistance of human colon cancer cell lines to doxorubicin.
Beaumont PO; Moore MJ; Ahmad K; Payne MM; Lee C; Riddick DS
Cancer Res; 1998 Mar; 58(5):947-55. PubMed ID: 9500455
[TBL] [Abstract][Full Text] [Related]
18. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
[TBL] [Abstract][Full Text] [Related]
19. Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence of lonidamine.
Fanciulli M; Bruno T; Giovannelli A; Gentile FP; Di Padova M; Rubiu O; Floridi A
Clin Cancer Res; 2000 Apr; 6(4):1590-7. PubMed ID: 10778993
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of anthracyclines by cellular peroxidase.
Reszka KJ; Wagner BA; Teesch LM; Britigan BE; Spitz DR; Burns CP
Cancer Res; 2005 Jul; 65(14):6346-53. PubMed ID: 16024637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
